An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records-Reference-Cited by-同舟云学术

An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records

Published:2019-02 Issue:2 Volume:33 Page:140-147
ISSN:1056-8727
Container-title:Journal of Diabetes and its Complications
language:en
Short-container-title:Journal of Diabetes and its Complications

Author:

Wysham Carol H.,Lefebvre Patrick,Pilon Dominic,Lafeuille Marie-Hélène,Emond Bruno,Kamstra Rhiannon,Pfeifer Michael,Duh Mei Sheng,Ingham Mike

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference25 articles.

1. Standards of medical care in diabetes—2016;Association AD;Diabetes Care,2016

2. HEDIS 2016 - Volume 1: Narrative;National Committee for Quality Assurance (NCQA),2016

3. Prescribing Information for Invokana (Canagliflozin);Janssen Pharmaceuticals Inc,2017

4. I. Prescribing Information for Januvia (Sitagliptin);Merck & Co,2015

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors;International Journal of Molecular Sciences;2022-03-26

2. Canagliflozin: from glycemic control to improvement of cardiovascular and renal prognosis in patients with type 2 diabetes mellitus. Resolution of Advisory Board;Diabetes mellitus;2022-01-04

3. Electronic Medical Record–Based Case Phenotyping for the Charlson Conditions: Scoping Review;JMIR Medical Informatics;2021-02-01

4. Type II diabetes mellitus: a review on recent drug based therapeutics;Biomedicine & Pharmacotherapy;2020-11

5. Electronic Medical Record–Based Case Phenotyping for the Charlson Conditions: Scoping Review (Preprint);2020-08-28